We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of... Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. Show more
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare &...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS...
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its co-founder and executive chairman, Matthew Rabinowitz, PhD, has been named R&D...
Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.251 | 2.59587200782 | 163.76 | 171.9499 | 160.18 | 1562399 | 167.14568434 | CS |
4 | 45.221 | 36.8279175829 | 122.79 | 171.9499 | 120.67 | 1655157 | 149.73638553 | CS |
12 | 55.001 | 48.6691443235 | 113.01 | 171.9499 | 110.57 | 1250356 | 136.17235611 | CS |
26 | 58.011 | 52.7372727273 | 110 | 171.9499 | 92.14 | 1304392 | 121.86266764 | CS |
52 | 113.551 | 208.503488799 | 54.46 | 171.9499 | 53.8801 | 1358719 | 99.65136793 | CS |
156 | 72.241 | 75.4317636003 | 95.77 | 171.9499 | 26.1 | 1414901 | 64.01034008 | CS |
260 | 129.571 | 337.073361082 | 38.44 | 171.9499 | 16.87 | 1181108 | 67.80029928 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions